Meropenem Hikma

Meropenem, the active ingredient in Meropenem Hikma, is a carbapenem antibiotic presented as an injectable powder for reconstitution for intravenous use. It treats severe bacterial infections such as intra‑abdominal, urinary tract, respiratory, bloodstream and central nervous system infections in hospitalized patients, and is commonly employed in intensive care settings.

GNH USA supplies Meropenem Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and healthcare institutions worldwide, with robust quality assurance, regulatory compliance and reliable cold‑chain logistics, ensuring timely delivery.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems.

- Complicated intra-abdominal infections: achieves bacterial eradication in severe abdominal sepsis. - Complicated urinary tract infections: provides effective clearance of resistant uropathogens. - Nosocomial pneumonia: improves clinical cure rates in hospital‑acquired lung infections. - Septicemia: rapidly reduces bloodstream bacterial load. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Meropenem may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and occasional. - Headache: transient cranial discomfort. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in transaminases. - Injection site reactions: pain or erythema at infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Hemolytic anemia: rare immune‑mediated destruction of red cells. - Renal toxicity: acute kidney injury in predisposed individuals.

Before initiating Meropenem therapy, clinicians should consider several precautionary measures to minimize risk.

- Renal function: adjust dose in patients with impaired clearance. - Seizure risk: avoid or monitor in individuals with a history of epilepsy or CNS disorders. - Hypersensitivity: assess for known β‑lactam allergy before use. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Concomitant nephrotoxic drugs: monitor renal parameters when combined with other nephrotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may reduce serum levels, risking seizure breakthrough. - Probenecid: can increase meropenem concentrations, potentially enhancing toxicity. - Carbapenem‑resistant organisms: concurrent use with other carbapenems may promote resistance.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may increase risk of ototoxicity when combined with aminoglycosides. - Anticoagulants (warfarin): monitor INR as infection may alter coagulation. - Oral contraceptives: possible reduced efficacy; advise alternative contraception.